HUP9901865A3 - Method and pharmaceutical composition for regulating lipid concentration - Google Patents

Method and pharmaceutical composition for regulating lipid concentration

Info

Publication number
HUP9901865A3
HUP9901865A3 HU9901865A HUP9901865A HUP9901865A3 HU P9901865 A3 HUP9901865 A3 HU P9901865A3 HU 9901865 A HU9901865 A HU 9901865A HU P9901865 A HUP9901865 A HU P9901865A HU P9901865 A3 HUP9901865 A3 HU P9901865A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
lipid concentration
regulating lipid
regulating
concentration
Prior art date
Application number
HU9901865A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21719566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9901865(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HUP9901865A2 publication Critical patent/HUP9901865A2/hu
Publication of HUP9901865A3 publication Critical patent/HUP9901865A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HU9901865A 1995-11-02 1996-10-02 Method and pharmaceutical composition for regulating lipid concentration HUP9901865A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US615595P 1995-11-02 1995-11-02

Publications (2)

Publication Number Publication Date
HUP9901865A2 HUP9901865A2 (hu) 1999-10-28
HUP9901865A3 true HUP9901865A3 (en) 2000-06-28

Family

ID=21719566

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901865A HUP9901865A3 (en) 1995-11-02 1996-10-02 Method and pharmaceutical composition for regulating lipid concentration

Country Status (27)

Country Link
US (3) US6124309A (hu)
EP (1) EP0858336B1 (hu)
JP (1) JPH11515025A (hu)
KR (2) KR100449604B1 (hu)
CN (2) CN1217656C (hu)
AR (1) AR004527A1 (hu)
AT (1) ATE348607T1 (hu)
AU (1) AU720853B2 (hu)
BG (1) BG64018B1 (hu)
BR (1) BR9611410A (hu)
CZ (1) CZ127198A3 (hu)
DE (1) DE69636783T2 (hu)
EA (1) EA000514B1 (hu)
ES (1) ES2279526T3 (hu)
GE (1) GEP20001898B (hu)
HK (1) HK1016509A1 (hu)
HU (1) HUP9901865A3 (hu)
IL (1) IL123902A (hu)
IS (1) IS4720A (hu)
NO (1) NO981961L (hu)
NZ (2) NZ319906A (hu)
PL (1) PL186714B1 (hu)
RO (1) RO120816B1 (hu)
SK (1) SK284142B6 (hu)
UA (1) UA46069C2 (hu)
WO (1) WO1997016184A1 (hu)
ZA (1) ZA969187B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
CZ127198A3 (cs) * 1995-11-02 1998-12-16 Warner-Lambert Company Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
SI1009400T1 (en) * 1997-08-29 2005-04-30 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
AU1591699A (en) * 1998-03-17 1999-10-11 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
PL346980A1 (en) * 1998-09-30 2002-03-11 Warner Lambert Co Method for preventing or delaying catheter-based revascularization
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
AU7717500A (en) * 1999-09-30 2001-04-30 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
EP1092432A1 (fr) 1999-10-15 2001-04-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Composes anti-ischemiques
KR20020050257A (ko) * 1999-11-05 2002-06-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ａｃａｔ 저해제에 의한 플라크 파열의 방지
EP1314423A4 (en) * 2000-09-01 2004-05-19 Sankyo Co MEDICAL CONNECTIONS
BR0114617A (pt) 2000-10-11 2005-12-13 Esperion Therapeutics Inc Composto, composição farmacêutica, métodos para tratar ou previnir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas
MXPA03003020A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de cetona y composiciones para el control del colesterol y usos relacionados.
CN1479721A (zh) 2000-10-11 2004-03-03 ͨ��ҽ�ƹ�˾ 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
EP1363879A2 (en) 2000-10-11 2003-11-26 Esperion Therapeutics Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
US20050020694A1 (en) * 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US20040192771A1 (en) * 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
WO2003077896A1 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Drug combination therapy
AU2003230918A1 (en) * 2002-04-10 2003-10-27 Esperion Therapeutics, Inc. Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses
JP4187141B2 (ja) * 2002-04-12 2008-11-26 興和株式会社 新規なトロンボモジュリン発現促進剤
CA2513660C (en) 2003-01-23 2012-05-08 Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
US7884106B2 (en) 2003-08-29 2011-02-08 Kowa Company, Ltd. Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
US20090110760A1 (en) * 2003-11-07 2009-04-30 Toyo Shinyaku Co., Ltd. Lipometabolism improver containing pine bark extract
US7705177B2 (en) 2003-12-24 2010-04-27 Esperion Therapuetics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CA2563693C (en) * 2004-04-19 2010-07-06 Loma Linda University Composition and method of decreasing renal ischemic damage
TW200605890A (en) * 2004-07-28 2006-02-16 Sankyo Co Pharmaceutical compositions for inhibiting arteriosclerosis
KR101021828B1 (ko) * 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
DK2018153T3 (da) 2006-04-26 2012-07-23 Rosemont Pharmaceuticals Ltd Flydende orale sammensætninger
US20130254787A1 (en) 2006-05-02 2013-09-26 Invidi Technologies Corporation Method and apparatus to perform real-time audience estimation and commercial selection suitable for targeted advertising
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
US8314080B2 (en) 2010-04-06 2012-11-20 Kuwait University Method of treating type I diabetes
CN103288702B (zh) * 2010-12-03 2015-09-16 上海科州药物研发有限公司 一种阿托伐他汀氨基酸盐的制备方法
US8586527B2 (en) * 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CN103304496A (zh) * 2012-03-08 2013-09-18 南京工业大学 一种合成申嗪霉素方法
PL2812005T3 (pl) 2012-05-16 2019-01-31 Prairie Berry Europe Gmbh Polihydroksylowane pentacykliczne kwasy triterpenowe jako inhibitory reduktazy HMG-CoA
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CA3144371A1 (en) 2019-06-21 2020-12-24 Esperion Therapeutics, Inc. Methods of making bempedoic acid and compositions of the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2048395A1 (en) * 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
EP0524595A1 (en) 1991-07-23 1993-01-27 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
WO1994009774A1 (en) * 1992-10-26 1994-05-11 Merck & Co., Inc. Biologically active compounds and process therefor
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
CZ127198A3 (cs) * 1995-11-02 1998-12-16 Warner-Lambert Company Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob

Also Published As

Publication number Publication date
US6093719A (en) 2000-07-25
DE69636783D1 (de) 2007-02-01
AU7253996A (en) 1997-05-22
RO120816B1 (ro) 2006-08-30
EA000514B1 (ru) 1999-10-28
IL123902A0 (en) 1998-10-30
HUP9901865A2 (hu) 1999-10-28
AU720853B2 (en) 2000-06-15
SK284142B6 (sk) 2004-10-05
KR19990067270A (ko) 1999-08-16
ATE348607T1 (de) 2007-01-15
KR100449604B1 (ko) 2004-11-16
CZ127198A3 (cs) 1998-12-16
IS4720A (is) 1998-04-17
UA46069C2 (uk) 2002-05-15
EP0858336A1 (en) 1998-08-19
IL123902A (en) 2003-01-12
ZA969187B (en) 1997-05-29
WO1997016184A1 (en) 1997-05-09
GEP20001898B (en) 2000-01-05
NO981961L (no) 1998-05-04
SK55798A3 (en) 1999-06-11
PL326365A1 (en) 1998-09-14
EP0858336B1 (en) 2006-12-20
NO981961D0 (no) 1998-04-30
CN1679953A (zh) 2005-10-12
US6143755A (en) 2000-11-07
CN1217656C (zh) 2005-09-07
KR20040029459A (ko) 2004-04-06
US6124309A (en) 2000-09-26
PL186714B1 (pl) 2004-02-27
BR9611410A (pt) 1999-01-05
NZ512484A (en) 2003-02-28
ES2279526T3 (es) 2007-08-16
HK1016509A1 (en) 1999-11-05
CN1201389A (zh) 1998-12-09
AR004527A1 (es) 1998-12-16
DE69636783T2 (de) 2007-10-18
BG64018B1 (bg) 2003-10-31
EA199800420A1 (ru) 1998-10-29
NZ319906A (en) 2000-02-28
BG102417A (en) 1999-01-29
JPH11515025A (ja) 1999-12-21

Similar Documents

Publication Publication Date Title
HUP9901865A3 (en) Method and pharmaceutical composition for regulating lipid concentration
HUP9801370A3 (en) Stable protein:phospholipid compositions and methods for production thereof
AU6281396A (en) Scavanging method and apparatus for post anesthesia care
AU6039096A (en) Method and apparatus for securing ligaments
IL117177A0 (en) Benzopyran-containing compounds and method for their use
AU5383796A (en) Method and apparatus for noninvasively determining hematocri t
EP0768114A3 (en) Method and device for homogenizing aerosol formulations
AU7091996A (en) Apparatus and method for microdermoabrasion
EP0876145A4 (en) TAX COMPOSITION AND PROCEDURE
HUP9901432A3 (en) Vaccine composition containing polyribosylribitol phosphate and method for making same
GB2298713B (en) Method and composition
AU5949296A (en) Reminder apparatus and method
AU4981896A (en) Liposome composition and method for administering liposome-loadable drugs
AU5301296A (en) Methods and compositions for regulating fadd
AU696892B2 (en) Maltitol composition and method for preparing it
AP9600784A0 (en) Oxathiolanes method for their preparation and pharmaceutical compositions containing them
EE9800164A (et) Farmatseutiline kompositsioon ja meetod epitelioomi raviks
HUP9702399A3 (en) Method for preparation taxol and its derivatives
HUP9602938A2 (en) Improved composition and method for acid gas treatment
AU1183797A (en) Method for measuring sensory irritation in vitro
GB9523843D0 (en) Cosmetic composition and method
AUPN598295A0 (en) Method and composition for reducing blood lipoprotein levels
HU9500156D0 (en) Pharmaceutical composition and process
GB2319480B (en) Apparatus and method for microdermoabrasion
GB9505605D0 (en) Composition and method for preparing natural lipid carriers